Drug intelligence / Profile preview

inavolisib + fulvestrant

Development stage: Unknown
Lead developer: Genentech
Modality: Small Molecules
Administration: Oral (inavolisib), Intramuscular Injection (fulvestrant)

Overview

inavolisib + fulvestrant is an investigational drug combination for the treatment of hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer. Inavolisib (GDC-0077) is a highly selective PI3Kα inhibitor that induces degradation of mutant p110α protein, specifically targeting tumors with PIK3CA mutations. Fulvestrant is an estrogen receptor antagonist used as endocrine therapy. The combination leverages both targeted inhibition of the PI3K pathway and hormonal blockade to improve outcomes in this patient population[2][8][10].

Targets

PIK3CA (Phosphoinositide 3-kinase alpha)ER (Estrogen receptor)

Beyond the preview

Go deeper on inavolisib + fulvestrant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inavolisib + fulvestrant.

Explore the full profile